Internet Pioneer In...
Health Care: Drugs
Durect Corporation (DRRX: NASDAQ)
$0.82 -0.01 | -1.10%
06/04/12 - 09:38 AM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 33.49M | 31.59M | 24.29M | 27.10M |
| Cost of Sales | 3.54M | 2.02M | 2.80M | 737.00K |
| Gross Operating Profit | 29.95M | 29.57M | 21.49M | 26.36M |
| Selling, General, and Administrative Expenses | 13.57M | 14.94M | 15.02M | 15.46M |
| Research & Development | 34.05M | 36.21M | 34.63M | 39.41M |
| Operating Income before D & A (EBITDA) | -17.68M | -21.58M | -28.17M | -28.51M |
| Depreciation & Amortization | 1.18M | 2.25M | 2.51M | 2.63M |
| Interest Income | 134.00K | 943.00K | 0.00 | 0.00 |
| Other Income - Net | 0.00 | 0.00 | 420.00K | 1.50M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | -13.48M |
| Total Income Before Interest Expenses (EBIT) | -18.72M | -22.89M | -30.25M | -43.12M |
| Interest Expense | 46.00K | 6.00K | 36.00K | 789.00K |
| Pre-Tax Income | -18.76M | -22.90M | -30.29M | -43.91M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -18.76M | -22.90M | -30.29M | -43.91M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -18.76M | -22.90M | -30.29M | -43.91M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -18.76M | -22.90M | -30.29M | -43.91M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-18.76M | -22.90M | -30.29M | -30.43M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -18.76M | -22.90M | -30.29M | -43.91M |
| Basic EPS from Continuing Ops. | -0.21 | -0.26 | -0.36 | -0.56 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.21 | -0.26 | -0.36 | -0.56 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.21 | -0.26 | -0.36 | -0.56 |
| Basic Normalized Net Income/Share | -0.21 | -0.26 | -0.36 | -0.39 |
| EPS fr Continuing Ops. | -0.21 | -0.26 | -0.36 | -0.56 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.21 | -0.26 | -0.36 | -0.56 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.21 | -0.26 | -0.36 | -0.56 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.21 | -0.26 | -0.36 | -0.39 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DRRX
- Portfolio NameUser Type
- ProRobert Bruce
- Userdonellisor
- UserTrading
- Userbaustin002 Portfolio 1
- UserBarron's Research Reports 1...
- Userhititbig
- Userbv2
- UserFBSPANKEY Portfolio 1
- Usersandw1ch Portfolio 1
- Usermiguele4 Portfolio 1
Latest DRRX Headlines from TheStreet
- Business Highlights 06.24.11 | 06:06 pm
- Durect Stock Gaps Down On Today's Open (DRRX) 06.24.11 | 09:06 am
- Pfizer, Pain Therapeutics Drug Rejected by FDA 06.24.11 | 08:06 am
- 10 Stocks to Watch: Alcoa, BP 04.12.11 | 06:04 am
- Biotech Calendar: 2011 FDA Drug Approvals 02.22.11 | 07:02 am
- DURECT Corporation To Participate In Upcoming Healthcare Conferences 09.07.10 | 06:09 pm
- DURECT Corporation Q1 2010 Earnings Call Transcript 05.11.10 | 01:05 am
- Durect Says Pain Patch Met Goals In Clinical Study 03.16.09 | 02:03 pm
- Thursday's Winners & Losers: Durect 05.08.08 | 04:05 pm
- Health Winners & Losers: Barr 05.08.08 | 04:05 pm
Press Releases for DRRX
- DURECT Receives Back U.S. And Canadian Product Rights To POSIDUR⢠- PR Newswire 03.29.12 | 04:03 pm
- DURECT Corporation Invites You To Join Its Fourth Quarter 2011 Earnings Conference Call - PR Newswire 02.24.12 | 09:02 am
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 02.23.12 | 11:02 am
- DURECT To Present At The BIO CEO & Investor Conference - PR Newswire 02.07.12 | 12:02 pm
- DURECT Receives Back European Product Rights To POSIDUR⢠- PR Newswire 01.30.12 | 04:01 pm
- DURECT Announces Top-line Data From BESST (POSIDUR® U.S. Pivotal Phase III Trial) - PR Newswire 01.05.12 | 04:01 pm
- DURECT Corporation To Participate In Upcoming Healthcare Conferences - PR Newswire 11.07.11 | 08:11 am
- DURECT Corporation Invites You To Join Its Third Quarter 2011 Earnings Conference Call - PR Newswire 10.26.11 | 05:10 pm
- DURECT Completes Enrollment In Pivotal U.S. Phase III Trial For POSIDUR® (BESST) - PR Newswire 09.06.11 | 07:09 am
- DURECT Corporation To Participate In Upcoming Healthcare Conferences - PR Newswire 08.31.11 | 04:08 pm
Partner Headlines for DRRX
- Pfizer Terminates Development and License Agreement Between Alpharma Ireland and DURECT - Benzinga 03.01.12 | 04:03 pm
- DURECT Announces Top-line Data from BESST; Did Not Reach Statistical Significance - Benzinga 01.05.12 | 04:01 pm
- 12 Healthcare Companies Looking at June Catalysts - Seeking Alpha 05.30.11 | 04:05 am
- Jefferies Reiterates Buy Rating on DURECT Corp. (DRRX) - Benzinga 08.05.10 | 09:08 am
- FDA Clears Hospira's Generic Drug - Analyst Blog - Zacks 06.25.10 | 01:06 pm
- UPDATE 1-Durect's pain drug shows mixed results in EU trial - Reuters 06.16.10 | 05:06 pm
- King Advances Pain Candidate - Analyst Blog - Zacks 04.08.10 | 06:04 pm
